Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review

Alexandra Hunter*, Michael Williams

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)
50 Downloads (Pure)

Abstract

This systematic review assessed the long-term outcomes for patients treated with intravitreal antivascular endothelial growth factor or dexamethasone for macular oedema (MO) secondary to retinal vein occlusion (RVO). Studies investigating patients of all ages with MO due to RVO only were included. The review was deliberately broad in scope, including comparative and non-comparative studies to ensure inclusion of real-world type evidence. Risk of bias was assessed. In total, 76 data sets were included (10 775 participants). Overall, mean best-corrected visual acuity (BCVA) improved from baseline to 5 years by 16.1 letters (p
Original languageEnglish
Article numbere001010
JournalBMJ Open Ophthalmology
Volume7
Issue number1
DOIs
Publication statusPublished - 14 Jun 2022

Keywords

  • Review
  • 1506
  • macula
  • retina
  • drugs
  • treatment medical
  • vision

Fingerprint

Dive into the research topics of 'Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review'. Together they form a unique fingerprint.

Cite this